Results 141 to 150 of about 399,874 (258)

The Programmed Placebo Effect in Patients with Syncope: Preliminary Clinical and Nanostructural Insights with a Hypothetical Quantum-Level Interpretation. [PDF]

J Clin Med
Hadžić B, Romčević N, Marković N, Petrović M, Bojić M, Milovanović B.   +5 more
europepmc   +1 more source

Compression-induced improvements in post-exercise recovery are associated with enhanced blood flow, and are not due to the placebo effect. [PDF]

Sci Rep, 2022
O'Riordan SF, Bishop DJ, Halson SL, Broatch JR.   +3 more
europepmc   +1 more source

Magnitude of the Digital Placebo Effect and Its Moderators on Generalized Anxiety Symptoms: Systematic Review and Meta-Analysis. [PDF]

J Med Internet Res
Hosono T, Tsutsumi R, Niwa Y, Kondoh M.
europepmc   +1 more source

Myths and Truths about Placebo Effect in Rehabilitation for Musculoskeletal Pain. [PDF]

Adv Ther, 2021
Iolascon G, Moretti A.
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Justice for Placebo: Placebo Effect in Clinical Trials and Everyday Practice. [PDF]

Medicines (Basel)
Knezevic NN, Sic A, Worobey S, Knezevic E.   +3 more
europepmc   +1 more source

Response to: Real effect vs placebo effect. [PDF]

J Clin Sleep Med, 2021
Vgontzas AN, Puzino K, Fernandez-Mendoza J.   +2 more
europepmc   +1 more source

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

The Placebo Effect in Chronic Thromboembolic Pulmonary Hypertension Trials: A Systematic Review and Meta-Analysis. [PDF]

Med Sci (Basel)
Caldeira D, Cazeiro DI, Plácido R, Ferreira F, Calé R, Pinto FJ.   +5 more
europepmc   +1 more source

Consideration in Randomized Placebo-Controlled Trial on Neck Pain to Avoid the Placebo Effect in Analgesic Action. [PDF]

Front Pharmacol, 2022
Sun YL, Yao M, Zhu YF, Yin MC, Liu JT, Chen X, Huang J, Dai YX, Wang WH, Ma ZB, Wang YJ, Cui XJ.   +11 more
europepmc   +1 more source